Equities Analysts Offer Predictions for KROS Q2 Earnings
Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) – Stock analysts at Leerink Partnrs reduced their Q2 2025 earnings per share estimates for Keros Therapeutics in a report issued on Tuesday, May 6th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($1.16) per share for the quarter, down from their previous estimate […]
Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) – Stock analysts at Leerink Partnrs reduced their Q2 2025 earnings per share estimates for Keros Therapeutics in a report issued on Tuesday, May 6th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($1.16) per share for the quarter, down from their previous estimate […]
